Profile
David M. Mott is listed as a director across Ardelyx Inc. (ARDX), Mersana Therapeutics, Inc. (MRSN), and Novavax, Inc. (NVAX) based on SEC filings. The latest filing date provided is February 24, 2026, and it shows no stock purchases or sales in connection with these board roles.
| Role | Director |
|---|
| Notability | 60/100 |
|---|
Board memberships
- Ardelyx Inc. (ARDX)
- Mersana Therapeutics, Inc. (MRSN)
- Novavax, Inc. (NVAX)
Awards & honors
- Serves as a director on multiple public biotech company boards
- Provides governance and strategic oversight in biopharmaceutical development
- Brings extensive experience in biotech investments and governance
Frequently Asked Questions
Who is MOTT DAVID M?
David M. Mott is listed as a director across Ardelyx Inc. (ARDX), Mersana Therapeutics, Inc. (MRSN), and Novavax, Inc. (NVAX) based on SEC filings. The latest filing date provided is February 24, 2026, and it shows no stock purchases or sales in connection with these board roles.…
How many SEC Form 4 filings has MOTT DAVID M submitted recently?
2 primary Form 4 filings in the last 90 days, covering 2 companies.
Has MOTT DAVID M been buying or selling stock?
Recorded transactions: 7 open-market purchases ($7.34M) and 0 open-market sales () across all tracked filings.
How accurate is MOTT DAVID M's historical track record?
Across 7 tracked purchases, MOTT DAVID M averaged +898.4% avg 30-day return with a 7143% 30-day win rate. InsiderAlpha rates the track record at 4/5 stars.
Where can I see all of MOTT DAVID M's SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.